Unisol

Unisol is an intervention being evaluated in a Phase 2, open-label, randomized, parallel group, placebo-controlled, single-center study sponsored by Deacon Biosciences, Inc. The study assesses its anti-microbial efficacy and safety following topical periocular administration in healthy volunteers, comparing it to DCN01. The name "Unisol" is highly non-specific, and other products with the same name exist, including a combination drug for benign prostatic hyperplasia (dutasteride and tamsulosin), veterinary antibiotics (enrofloxacin) and anti-inflammatories (sodium salicylate), a veterinary vitamin supplement, and a discontinued preservative-free saline solution for contact lenses. The specific composition and mechanism of action of the "Unisol" used in this clinical trial are not detailed in the provided context or general search results.

Brand names

Unisol